|
Exagen Inc. (XGN) DCF Valuation
US | Healthcare | Medical - Diagnostics & Research | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Exagen Inc. (XGN) Bundle
Discover Exagen Inc.'s (XGN) true potential with our professional-grade DCF Calculator! Adjust key assumptions, explore various scenarios, and assess how changes influence Exagen Inc.'s (XGN) valuation – all within a single Excel template.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.4 | 42.0 | 48.3 | 45.6 | 52.5 | 56.3 | 60.3 | 64.7 | 69.3 | 74.3 |
| Revenue Growth, % | 0 | 3.93 | 15.07 | -5.66 | 15.33 | 7.17 | 7.17 | 7.17 | 7.17 | 7.17 |
| EBITDA | -7.9 | -13.7 | -23.1 | -43.1 | -19.2 | -26.0 | -27.9 | -29.9 | -32.0 | -34.3 |
| EBITDA, % | -19.64 | -32.53 | -47.83 | -94.62 | -36.45 | -46.21 | -46.21 | -46.21 | -46.21 | -46.21 |
| Depreciation | .6 | .5 | .9 | 2.1 | 2.2 | 1.5 | 1.6 | 1.7 | 1.9 | 2.0 |
| Depreciation, % | 1.46 | 1.3 | 1.96 | 4.63 | 4.13 | 2.7 | 2.7 | 2.7 | 2.7 | 2.7 |
| EBIT | -8.5 | -14.2 | -24.1 | -45.2 | -21.3 | -27.5 | -29.5 | -31.6 | -33.9 | -36.3 |
| EBIT, % | -21.1 | -33.83 | -49.8 | -99.25 | -40.57 | -48.91 | -48.91 | -48.91 | -48.91 | -48.91 |
| Total Cash | 72.1 | 57.4 | 99.4 | 62.4 | 36.5 | 52.9 | 56.7 | 60.7 | 65.1 | 69.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 5.7 | 8.9 | 9.7 | 6.1 | 6.6 | 9.1 | 9.8 | 10.5 | 11.3 | 12.1 |
| Account Receivables, % | 14.15 | 21.23 | 19.99 | 13.34 | 12.47 | 16.23 | 16.23 | 16.23 | 16.23 | 16.23 |
| Inventories | 1.4 | 1.2 | 1.1 | 1.8 | 2.9 | 2.0 | 2.2 | 2.3 | 2.5 | 2.7 |
| Inventories, % | 3.53 | 2.87 | 2.26 | 3.94 | 5.46 | 3.61 | 3.61 | 3.61 | 3.61 | 3.61 |
| Accounts Payable | 1.5 | 3.0 | 2.5 | 3.0 | 3.1 | 3.2 | 3.5 | 3.7 | 4.0 | 4.3 |
| Accounts Payable, % | 3.65 | 7.18 | 5.16 | 6.69 | 5.96 | 5.73 | 5.73 | 5.73 | 5.73 | 5.73 |
| Capital Expenditure | -.4 | -.5 | -2.4 | -4.3 | -.8 | -2.0 | -2.2 | -2.3 | -2.5 | -2.7 |
| Capital Expenditure, % | -0.99785 | -1.08 | -4.91 | -9.48 | -1.58 | -3.61 | -3.61 | -3.61 | -3.61 | -3.61 |
| Tax Rate, % | -0.1395 | -0.1395 | -0.1395 | -0.1395 | -0.1395 | -0.1395 | -0.1395 | -0.1395 | -0.1395 | -0.1395 |
| EBITAT | -8.5 | -14.1 | -24.2 | -45.0 | -21.4 | -27.5 | -29.5 | -31.6 | -33.8 | -36.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -14.0 | -15.5 | -26.8 | -43.7 | -21.5 | -29.7 | -30.6 | -32.8 | -35.1 | -37.6 |
| WACC, % | 10.44 | 10.42 | 10.44 | 10.42 | 10.44 | 10.43 | 10.43 | 10.43 | 10.43 | 10.43 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -122.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -38 | |||||||||
| Terminal Value | -455 | |||||||||
| Present Terminal Value | -277 | |||||||||
| Enterprise Value | -400 | |||||||||
| Net Debt | -13 | |||||||||
| Equity Value | -387 | |||||||||
| Diluted Shares Outstanding, MM | 18 | |||||||||
| Equity Value Per Share | -21.90 |
What You Will Receive
- Comprehensive Financial Model: Exagen Inc.'s (XGN) actual data facilitates accurate DCF valuation.
- Complete Forecast Control: Modify revenue growth, profit margins, WACC, and other essential parameters.
- Real-Time Calculations: Instant updates allow you to view results immediately as you adjust inputs.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation presentations.
- Flexible and Reusable: Designed for adaptability, enabling repeated application for in-depth forecasts.
Key Features
- Comprehensive Historical Data: Exagen Inc.’s historical financial statements and pre-filled projections.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Valuation: Instantly view Exagen Inc.’s intrinsic value recalculating on the fly.
- Intuitive Visualizations: Interactive dashboard charts present valuation outcomes and essential metrics.
- Designed for Precision: A reliable tool tailored for analysts, investors, and finance professionals.
How It Works
- 1. Access the Template: Download and open the Excel file containing Exagen Inc.’s (XGN) preloaded data.
- 2. Modify Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures.
- 3. See Results Instantly: The DCF model automatically computes intrinsic value and NPV.
- 4. Explore Scenarios: Evaluate various forecasts to assess different valuation possibilities.
- 5. Present with Assurance: Deliver professional valuation insights to enhance your decision-making.
Why Choose Exagen Inc. (XGN) Calculator?
- Precision: Utilizes Exagen's real financial data for reliable calculations.
- Adaptability: Crafted to allow users to easily adjust and test various inputs.
- Efficiency: Eliminate the need to create a financial model from the ground up.
- Expert-Level: Built with the accuracy and functionality expected by financial professionals.
- Intuitive: Simple to navigate, suitable for users with varying levels of financial expertise.
Who Should Use This Product?
- Investors: Evaluate Exagen Inc.’s (XGN) market position before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess financial forecasts.
- Startup Founders: Understand the valuation strategies of established companies like Exagen Inc. (XGN).
- Consultants: Create detailed valuation analyses and reports for client engagements.
- Students and Educators: Utilize current data from Exagen Inc. (XGN) to learn and teach valuation principles.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Exagen Inc. (XGN) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), encompassing parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models illustrating intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to aid in analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Exagen Inc. (XGN).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to facilitate result analysis.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.